Tritonix.ai

News / Taiwan / cnyes

Huaan Plans $300 Million Capital Raise to Accelerate Drug Trials and Licensing

Health Technology · Biotechnology · cnyes · 2026-09-04

6657

Taiwan-based Huaan (6657) is set to raise NT$300 million through a new share issuance to fund clinical trials for its F705PD and F703EB drug candidates.

What Happened

Capital Raising: Huaan's board has approved a cash capital increase to issue 10,000 new shares at a tentative price of NT$30 per share, aiming to raise NT$300 million. The proceeds will be used to bolster working capital and accelerate the clinical development of two key drug candidates, strengthening the company's position in international licensing negotiations.

Clinical Pipeline: The Parkinson's disease candidate F705PD has completed Phase I trials and is preparing data for FDA review for Phase II, while the epidermolysis bullosa treatment F703EB is advancing through Phase II trials in Taiwan and the U.S. with orphan drug designations.

Research Milestones: The company's most advanced candidate, F703DFU for diabetic foot ulcers, has submitted interim analysis data to the FDA. Positive results could potentially expedite the regulatory pathway and shorten the time to market for this key product.

Future Outlook: Chairman Chen Han-min expressed optimism for the next two years, noting that the company is entering a harvest period as its core pipeline matures. The firm continues to leverage its proprietary ENERGI cell self-healing platform to target high-value niche markets.

Read original

More in Health Technology

Adimmune August Revenue Grows 34% YoY

Health Technology · cnyes · 2026-09-04

Adimmune (4142) reported August revenue of NT$97.92 million, a 34.46% year-over-year increase, showing resilience compared to the biotech sector index.

4142

FTSE Russell Quarterly Review: PharmaEssentia Joins Taiwan 50 Index, Alchip Removed

Health Technology · economic_daily · 2026-09-04

The Taiwan Index Plus Corporation has announced its quarterly index adjustments, with PharmaEssentia entering the Taiwan 50 index while Alchip is removed, effective September 21.

0050

FTSE Russell Announces Taiwan Index Rebalancing: PharmaEssentia In, Alchip Out

Health Technology · economic_daily · 2026-09-04

FTSE Russell has unveiled its latest quarterly index review for Taiwan, with PharmaEssentia joining the Taiwan 50 Index while Alchip-KY is removed.

1301, 2371, 2379, 2441, 2615, 2637, 2845, 2855, 3006, 3189, 3406, 3450, 3481, 3661, 4583, 4919, 6005, 6446, 6944, 6949, 7610, 8039, 8454

Latest in Taiwan

Taiwan Stocks Face Volatility; Institutional Investors Target 10 'Triple-A' Stocks

Electronic Technology · economic_daily · 2026-09-04

As the Taiwan stock market navigates high-level volatility amid Fed rate hike signals, institutional investors are accumulating 10 stocks with strong fundamentals.

Winbond Electronics Reports Record August Revenue for Ninth Consecutive Month

Electronic Technology · economic_daily · 2026-09-04

Winbond Electronics achieved record-breaking monthly revenue in August, driven by tight supply and robust demand in the memory market.

2344

Mirle Automation Sees July Profit Surge, EPS Hits NT$0.2

Electronic Technology · economic_daily · 2026-09-04

Mirle Automation reported a strong profit increase in July, driven by AI-related demand and a robust order backlog exceeding NT$15 billion.

2464

Baohuan's August Revenue Surges 62.8% Driven by Outdoor and Military Product Demand

Process Industries · cnyes · 2026-09-04

Baohuan (1342-TW) reported a 62.83% year-over-year revenue increase in August, fueled by a doubling in shipments for its outdoor and military product lines.

1342